Search

Search Constraints

You searched for: Author/Creator Hauser, Ingeborg A.

Search Results

1. ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?. Issue 3 (September 2020)

2. CD4+ T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients. Issue 9 (30th April 2020)

3. COUNTRY-DEPENDENT OUTCOME DIFFERENCES AFTER KIDNEY TRANSPLANTATION IN FRANCE VS. GERMANY – AN ADDITIONAL ANALYSIS OF THE ATHENA STUDY. Issue 3 (September 2020)

4. CTGF Is Expressed During Cystic Remodeling in the PKD/Mhm (cy/+) Rat Model for Autosomal-Dominant Polycystic Kidney Disease (ADPKD). (December 2017)

5. Effect of everolimus‐based drug regimens on CMV‐specific T‐cell functionality after renal transplantation: 12‐month ATHENA subcohort‐study results. Issue 4 (28th December 2020)

6. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. (20th August 2014)

7. Five‐year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low‐exposure cyclosporine versus standard therapy. Issue 12 (3rd June 2018)

8. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Issue 11 (November 2018)

9. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial. Issue 11 (11th November 2022)